Shifting the early diagnostic paradigm
Supporting radiologists and clinicians worldwide in screening, early diagnosis & treatment of cancer and fibrotic disease
Next generation end-to-end AI/ML tech-based CADe CADx Software as Medical Devices (SaMDs) with unprecedented performance
Our goal is to reduce cancers and fibrotic diseases burdens by helping radiologists and clinicians identify disease at the earliest possible stage, allowing better care while avoiding unnecessary procedures and reducing healthcare costs.
With iBiopsy®, we are committed to improving patients’ lives with a portfolio of the most accurate AI/ML tech-based Software as Medical Devices (SaMDs) dedicated to early diagnosis of cancers & fibrotic diseases.
A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician.” A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease.” Source: FDA
Enabling the early detection & characterization of cancer and fibrotic disease to improve patients’ lives
Early and accurate diagnosis
Shorter time to treatment
Reduced disease burden and improved examination adherence
Decrease false positives and false negative results
Reduced image review time and intra & inter-operator variability
Increased patient compliance thanks to greater trust in diagnostic accuracy
Healthcare Organizations Benefits
Fewer procedures to reach final diagnosis
Reduced need for late-stage & costly drug treatments
Leveraging Median’s medical imaging expertise
Combining the power of AI & Data Science
iBiopsy® provides a portfolio of innovative end-to-end AI/ML tech-based Software as Medical Devices (SaMDs) in indications where early diagnosis is an unmet need.
iBiopsy®’s goal is to shift the medical diagnostic paradigm, in Lung Cancer, Liver Cancer and Liver Fibrosis Disease.
The power of iBiopsy®
Leveraging Median’s medical imaging expertise, combined with the power of AI & Data Science, iBiopsy® brings the power to:
- Achieve unprecedented diagnostic accuracy
- Decrease false negative & false positive results
- Improve patients’ lives
- Optimize radiologist time
- Increase workflow standardization
- Reduce unnecessary procedures and healthcare spending
Lung Cancer Screening (LCS) and incidental pulmonary nodules (IPN)
Very early Hepatocellular Carcinoma (HCC)
Liver fibrosis in nonalcoholic steatohepatitis (NASH)
Median Technologies to participate in the 2022 European Congress of Radiology (ECR), July 13 – 17, 2022, Vienna, Austria, with two presentations on iBiopsy®
Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device
Median Technologies announces design completion of its iBiopsy® Lung Cancer Screening end-to-end CADe/CADx Software as Medical Device (SaMD) with outstanding sensitivity & specificity performance
Median Technologies files FDA 513(g) regulatory submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device
Learn more about iBiopsy®
Our team welcomes you to explore further our unprecedented technology for diagnostic imaging.